Genetically Engineered Animals, 54360-54361 [E8-21977]
Download as PDF
54360
Federal Register / Vol. 73, No. 183 / Friday, September 19, 2008 / Notices
OMB Control Number: 0572–0107.
Summary of Collection: The Rural
Electrification Act of 1936, 7 U.S.C. 901
et seq., as amended, (RE ACT) in Sec.
4 (7 U.S.C. 904) authorizes and
empowers the Administrator of the
Rural Utilities Service (RUS) to make
loans in the several States and
Territories of the United States for rural
electrification and the furnishing and
improving of electric energy to persons
in rural areas. These loans are for a term
of up to 35 years and are secured by a
first mortgage on the borrower’s electric
system. In the interest of protecting loan
security and accomplishing the
statutory objective of a sound program
of rural electrification, Section 4 of the
RE Act further requires that RUS make
or guarantee a loan only if there is
reasonable assurance that the loan,
together with all outstanding loans and
obligations of the borrower, will be
repaid in full within the time agreed.
RUS will collect information using
various RUS forms.
Need and Use of the Information:
RUS will collect information to
implement certain provisions of the
RUS standard form of loan documents
regarding the borrower’s purchase of
materials and equipment and the
construction of its electric system by
contract or force account. The
information will be used by RUS
electric borrowers and their contractors
and by RUS. If standard forms were not
used, borrowers would need to prepare
their own documents at a significant
expense; and each document submitted
by a borrower would require extensive
and costly review by both RUS and the
Office of the General Counsel.
Description of Respondents: Not-forprofit institutions; Business or other forprofit.
Number of Respondents: 1,210.
Frequency of Responses: Reporting:
On occasion.
Total Burden Hours: 104.
Charlene Parker,
Departmental Information Collection
Clearance Officer.
[FR Doc. E8–21907 Filed 9–18–08; 8:45 am]
BILLING CODE 3410–15–P
DEPARTMENT OF AGRICULTURE
Animal and Plant Health Inspection
Service
jlentini on PROD1PC65 with NOTICES
[Docket No. APHIS–2006–0188]
Genetically Engineered Animals
Animal and Plant Health
Inspection Service, USDA.
AGENCY:
17:25 Sep 18, 2008
Request for information.
SUMMARY: The Animal and Plant Health
Inspection Service (APHIS) is seeking
public comment and scientific and
technical empirical data and
information concerning ongoing and
future research on genetically
engineered animals. APHIS’ interest is
to ensure that genetically engineered
animals imported into the United States
or moved interstate do not present risks
to U.S. livestock health. We also seek
comment on what types of actions and
approaches APHIS should consider in
addressing any such risks that would
complement the Food and Drug
Administration’s (FDA’s) oversight,
described in draft guidance elsewhere in
this issue of the Federal Register.
DATES: We will consider all comments
that we receive on or before November
18, 2008.
ADDRESSES: You may submit comments
by either of the following methods:
• Federal eRulemaking Portal: Go to
https://www.regulations.gov/fdmspublic/
component/main?main=DocketDetail&
d=APHIS–2006–0188 to submit or view
comments and to view supporting and
related materials available
electronically.
• Postal Mail/Commercial Delivery:
Please send two copies of your comment
to Docket No. APHIS–2006–0188,
Regulatory Analysis and Development,
PPD, APHIS, Station 3A–03.8, 4700
River Road Unit 118, Riverdale, MD
20737–1238. Please state that your
comment refers to Docket No. APHIS–
2006–0188.
Reading Room: You may read any
comments that we receive on this
docket in our reading room. The reading
room is located in room 1141 of the
USDA South Building, 14th Street and
Independence Avenue, SW.,
Washington, DC. Normal reading room
hours are 8 a.m. to 4:30 p.m., Monday
through Friday, except holidays. To be
sure someone is there to help you,
please call (202) 690–2817 before
coming.
Other Information: Additional
information about APHIS and its
programs is available on the Internet at
https://www.aphis.usda.gov.
FOR FURTHER INFORMATION CONTACT:
Biotechnology Regulatory Services,
APHIS, 4700 River Road Unit 146,
Riverdale, MD 20737–1236; 301–734–
5720.
SUPPLEMENTARY INFORMATION:
RIN 0579–AC37
VerDate Aug<31>2005
ACTION:
Jkt 214001
Background
In 1986, the Office of Science and
Technology Policy (OSTP) under the
Executive Office of the President
PO 00000
Frm 00005
Fmt 4703
Sfmt 4703
published a policy document known as
the Coordinated Framework for the
Regulation of Biotechnology (the
Coordinated Framework).1 This policy
document describes the system for
coordinating the activities of the Federal
agencies responsible for regulating all
GE organisms:2 The Environmental
Protection Agency (EPA), the U.S.
Department of Health and Human
Services’ (HHS) Food and Drug
Administration (FDA), and the U.S.
Department of Agriculture (USDA),
specifically the Animal and Plant
Health Inspection Service (APHIS). The
foundation of the Coordinated
Framework is that existing health and
safety laws administered by these
Federal agencies provide a sound
network of agency authorities for the
regulation of GE organisms and
products.
Roles of APHIS and Other Agencies in
the Regulation of GE Animals
USDA and FDA both have authorities
relevant to the oversight of GE animals.
FDA has authority over new animal
drugs under the Federal Food, Drug, and
Cosmetic Act (FFDCA, 21 U.S.C. 321 et
seq.). Elsewhere in the issue of the
Federal Register, FDA is announcing
the availability of draft guidance for
public comment clarifying its oversight
of GE animals under the new animal
drug provisions of the FFDCA. The draft
guidance explains that where a
recombinant DNA construct in a GE
animal is intended to affect the structure
or function of the body of the GE
animal, that construct is a new animal
drug 3 regardless of the intended use of
products that may be produced by the
GE animal. The FFDCA requires that
each new animal drug be approved
through a new animal drug application
(NADA) based on a demonstration that
it is safe and effective for its intended
use. FDA has been working with
developers of GE animals for almost 20
years and the draft guidance is intended
to clarify requirements and
recommendations for producers and
developers of GE animals and their
products.
1 Coordinated Framework for the Regulation of
Biotechnology: June 26, 1986; 51 FR 23302;
https://usbiotechreg.nbii.gov/CoordinatedFramework
ForRegulationOfBiotechnology1986.pdf.
2 In addition to discussing the regulatory
responsibilities of these agencies for GE organisms
and other products, the Coordinated Framework
also discusses the responsibilities of agencies with
jurisdiction over GE research (the National
Institutes of Health, the National Science
Foundation, EPA, and USDA’s Agricultural
Research Service).
3 In accordance with the definition of ‘‘new
animal drug’’ in 21 U.S.C. 321(v).
E:\FR\FM\19SEN1.SGM
19SEN1
Federal Register / Vol. 73, No. 183 / Friday, September 19, 2008 / Notices
The USDA has provided Federal
leadership in protecting U.S. livestock
health for more than 120 years. APHIS
is authorized, under the Animal Health
Protection Act (AHPA) (7 U.S.C. 8301 et
seq.), to protect the health of U.S.
livestock by preventing the introduction
and spread of livestock diseases and
pests into and within the United States.
Based on that authority, APHIS may
broadly consider the potential effects of
animals with GE traits on the health of
the overall U.S. livestock population,
while FDA is more focused on the direct
effects of genetic engineering on
individual animals based on their
authority under the FFDCA. Given these
complementary authorities, APHIS and
FDA have been discussing their
respective roles in overseeing GE
animals for some time. FDA’s release for
public comment of its draft guidance on
GE animals provides an excellent
opportunity for APHIS to solicit public
comment on the potential effects of
animals with GE traits on U.S. livestock
health.
APHIS particularly seeks the
following information:
1. What research on GE animals is
currently being conducted or planned
for the future?
2. What, if any, implications would
activities such as the importation and
interstate movement of such animals
have for the health of the U.S. livestock
population?
3. What, if any, activities should
APHIS consider with respect to U.S.
livestock health under the AHPA that
would complement the requirements
and recommendations described in
FDA’s draft guidance?
APHIS welcomes comments and
scientific and technical information and
data relevant to these issues. We will
consider all comments and information
we receive in determining the
appropriate role for APHIS with regard
to GE animals and will continue to
collaborate closely with FDA.
This action has been determined to be
significant for the purposes of Executive
Order 12866 and, therefore, has been
reviewed by the Office of Management
and Budget.
jlentini on PROD1PC65 with NOTICES
Authority: 7 U.S.C. 8301–8317; 7 CFR 2.22,
2.80, and 371.
Done in Washington, DC, this 16th day of
September 2008.
Bruce Knight,
Under Secretary for Marketing and Regulatory
Programs.
[FR Doc. E8–21977 Filed 9–18–08; 8:45 am]
BILLING CODE 3410–34–P
VerDate Aug<31>2005
17:25 Sep 18, 2008
Jkt 214001
DEPARTMENT OF AGRICULTURE
Food Safety and Inspection Service
[Docket No. FSIS–2008–0032]
Codex Alimentarius Commission: 2nd
Session of the Codex ad hoc
Intergovernmental Task Force on
Antimicrobial Resistance
Office of the Under Secretary
for Food Safety, USDA.
ACTION: Notice of public meeting.
AGENCY:
SUMMARY: The Office of the Under
Secretary for Food Safety, United States
Department of Agriculture (USDA), and
the Food and Drug Administration
(FDA) are sponsoring a public meeting
on September 25, 2008, to discuss the
agenda items coming before the 2nd
session of the Codex ad hoc
Intergovernmental Task Force on
Antimicrobial Resistance (AMR) and to
present draft U.S. positions on the
agenda items. The 2nd session of the
AMR will be held in Seoul, Korea,
October 20–24, 2008. The Under
Secretary and FDA recognize the
importance of providing interested
parties the opportunity to comment on
the agenda items that will be discussed
at this forthcoming session of AMR.
DATES: The public meeting is scheduled
for Thursday, September 25, 2008, from
1 p.m. to 3 p.m.
ADDRESSES: The public meeting will be
held at FDA, 7519 Standish Place, Room
152, Rockville, MD.
Documents related to the 2nd session
of the AMR will be accessible via the
World Wide Web at the following
address: https://
www.codexalimentarius.net/
current.asp.
For Further Information About the 2nd
Session of the AMR Contact: U.S.
Delegate, Dr. David White, Director,
National Antimicrobial Resistance
Monitoring System (NARMS), FDA,
Center for Veterinary Medicine, Office
of Research, 8401 Muirkirk Rd., Laurel,
MD 20798, Phone: (301) 210–4181,
E-mail: david.white@fda.hhs.gov.
For Further Information About the
Public Meeting Contact: Edith Kennard,
Staff Officer, U.S. Codex Office, Food
Safety and Inspection Service (FSIS),
Room 4861, South Building, 1400
Independence Avenue, SW.,
Washington, DC 20250, Phone: (202)
720–5261, Fax: (202) 720–3157, E-mail:
edith.kennard@fsis.usda.gov.
SUPPLEMENTARY INFORMATION:
Background
The Codex Alimentarius (Codex) was
established in 1963 by two United
PO 00000
Frm 00006
Fmt 4703
Sfmt 4703
54361
Nations organizations, the Food and
Agriculture Organization (FAO) and the
World Health Organization (WHO).
Through adoption of food standards,
codes of practice, and other guidelines
developed by its committees, and by
promoting their adoption and
implementation by governments, Codex
seeks to protect the health of consumers
and ensure that fair practices are used
in trade.
The Codex ad hoc Intergovernmental
Task Force on AMR was established by
the 29th Session of the Codex
Alimentarius Commission in 2006 to
develop science-based guidance to be
used to assess the risks to human health
associated with the presence in food
and feed, including aquaculture, and the
transmission through food and feed of
antimicrobial resistant microorganisms
and antimicrobial resistance genes. The
AMR Task Force would also consider
appropriate risk management options to
reduce such risk. The Task Force is
hosted by the Republic of Korea.
Issues To Be Discussed at the Public
Meeting
The following items on the agenda for
the 2nd session of the AMR will be
discussed during the public meeting:
• Matters Referred to the Committee
from Other Codex Bodies
• Information on the Work by FAO,
WHO, and the World Organization for
Animal Health on Antimicrobial
Resistance
• Proposed Draft Risk Assessment
Guidance Regarding Foodborne
Antimicrobial Resistant Microorganisms
(Report of the Working Group)
• Proposed Draft Guidance on
Creating Risk Profiles for Antimicrobial
Resistant Foodborne Microorganisms for
Setting Risk Assessment and
Management Priorities (Report of the
Working Group)
• Proposed Draft Risk Management
Guidance to Contain Foodborne
Antimicrobial Resistant Microorganisms
(Report of the Working Group)
Each issue listed will be fully
described in documents distributed, or
to be distributed, by the Korean
Secretariat to the meeting. Members of
the public may access copies of these
documents at https://
www.codexalimentarius.net/
current.asp.
Public Meeting
At the September 25, 2008, public
meeting, draft U.S. positions on these
agenda items will be described and
discussed, and attendees will have the
opportunity to pose questions and offer
comments. Written comments may be
offered at the meeting or sent to the U.S.
E:\FR\FM\19SEN1.SGM
19SEN1
Agencies
[Federal Register Volume 73, Number 183 (Friday, September 19, 2008)]
[Notices]
[Pages 54360-54361]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-21977]
-----------------------------------------------------------------------
DEPARTMENT OF AGRICULTURE
Animal and Plant Health Inspection Service
[Docket No. APHIS-2006-0188]
RIN 0579-AC37
Genetically Engineered Animals
AGENCY: Animal and Plant Health Inspection Service, USDA.
ACTION: Request for information.
-----------------------------------------------------------------------
SUMMARY: The Animal and Plant Health Inspection Service (APHIS) is
seeking public comment and scientific and technical empirical data and
information concerning ongoing and future research on genetically
engineered animals. APHIS' interest is to ensure that genetically
engineered animals imported into the United States or moved interstate
do not present risks to U.S. livestock health. We also seek comment on
what types of actions and approaches APHIS should consider in
addressing any such risks that would complement the Food and Drug
Administration's (FDA's) oversight, described in draft guidance
elsewhere in this issue of the Federal Register.
DATES: We will consider all comments that we receive on or before
November 18, 2008.
ADDRESSES: You may submit comments by either of the following methods:
Federal eRulemaking Portal: Go to https://
www.regulations.gov/fdmspublic/component/
main?main=DocketDetail&d=APHIS-2006-0188 to submit or view comments and
to view supporting and related materials available electronically.
Postal Mail/Commercial Delivery: Please send two copies of
your comment to Docket No. APHIS-2006-0188, Regulatory Analysis and
Development, PPD, APHIS, Station 3A-03.8, 4700 River Road Unit 118,
Riverdale, MD 20737-1238. Please state that your comment refers to
Docket No. APHIS-2006-0188.
Reading Room: You may read any comments that we receive on this
docket in our reading room. The reading room is located in room 1141 of
the USDA South Building, 14th Street and Independence Avenue, SW.,
Washington, DC. Normal reading room hours are 8 a.m. to 4:30 p.m.,
Monday through Friday, except holidays. To be sure someone is there to
help you, please call (202) 690-2817 before coming.
Other Information: Additional information about APHIS and its
programs is available on the Internet at https://www.aphis.usda.gov.
FOR FURTHER INFORMATION CONTACT: Biotechnology Regulatory Services,
APHIS, 4700 River Road Unit 146, Riverdale, MD 20737-1236; 301-734-
5720.
SUPPLEMENTARY INFORMATION:
Background
In 1986, the Office of Science and Technology Policy (OSTP) under
the Executive Office of the President published a policy document known
as the Coordinated Framework for the Regulation of Biotechnology (the
Coordinated Framework).\1\ This policy document describes the system
for coordinating the activities of the Federal agencies responsible for
regulating all GE organisms:\2\ The Environmental Protection Agency
(EPA), the U.S. Department of Health and Human Services' (HHS) Food and
Drug Administration (FDA), and the U.S. Department of Agriculture
(USDA), specifically the Animal and Plant Health Inspection Service
(APHIS). The foundation of the Coordinated Framework is that existing
health and safety laws administered by these Federal agencies provide a
sound network of agency authorities for the regulation of GE organisms
and products.
---------------------------------------------------------------------------
\1\ Coordinated Framework for the Regulation of Biotechnology:
June 26, 1986; 51 FR 23302; https://usbiotechreg.nbii.gov/
CoordinatedFrameworkForRegulationOfBiotechnology1986.pdf.
\2\ In addition to discussing the regulatory responsibilities of
these agencies for GE organisms and other products, the Coordinated
Framework also discusses the responsibilities of agencies with
jurisdiction over GE research (the National Institutes of Health,
the National Science Foundation, EPA, and USDA's Agricultural
Research Service).
---------------------------------------------------------------------------
Roles of APHIS and Other Agencies in the Regulation of GE Animals
USDA and FDA both have authorities relevant to the oversight of GE
animals. FDA has authority over new animal drugs under the Federal
Food, Drug, and Cosmetic Act (FFDCA, 21 U.S.C. 321 et seq.). Elsewhere
in the issue of the Federal Register, FDA is announcing the
availability of draft guidance for public comment clarifying its
oversight of GE animals under the new animal drug provisions of the
FFDCA. The draft guidance explains that where a recombinant DNA
construct in a GE animal is intended to affect the structure or
function of the body of the GE animal, that construct is a new animal
drug \3\ regardless of the intended use of products that may be
produced by the GE animal. The FFDCA requires that each new animal drug
be approved through a new animal drug application (NADA) based on a
demonstration that it is safe and effective for its intended use. FDA
has been working with developers of GE animals for almost 20 years and
the draft guidance is intended to clarify requirements and
recommendations for producers and developers of GE animals and their
products.
---------------------------------------------------------------------------
\3\ In accordance with the definition of ``new animal drug'' in
21 U.S.C. 321(v).
---------------------------------------------------------------------------
[[Page 54361]]
The USDA has provided Federal leadership in protecting U.S.
livestock health for more than 120 years. APHIS is authorized, under
the Animal Health Protection Act (AHPA) (7 U.S.C. 8301 et seq.), to
protect the health of U.S. livestock by preventing the introduction and
spread of livestock diseases and pests into and within the United
States. Based on that authority, APHIS may broadly consider the
potential effects of animals with GE traits on the health of the
overall U.S. livestock population, while FDA is more focused on the
direct effects of genetic engineering on individual animals based on
their authority under the FFDCA. Given these complementary authorities,
APHIS and FDA have been discussing their respective roles in overseeing
GE animals for some time. FDA's release for public comment of its draft
guidance on GE animals provides an excellent opportunity for APHIS to
solicit public comment on the potential effects of animals with GE
traits on U.S. livestock health.
APHIS particularly seeks the following information:
1. What research on GE animals is currently being conducted or
planned for the future?
2. What, if any, implications would activities such as the
importation and interstate movement of such animals have for the health
of the U.S. livestock population?
3. What, if any, activities should APHIS consider with respect to
U.S. livestock health under the AHPA that would complement the
requirements and recommendations described in FDA's draft guidance?
APHIS welcomes comments and scientific and technical information
and data relevant to these issues. We will consider all comments and
information we receive in determining the appropriate role for APHIS
with regard to GE animals and will continue to collaborate closely with
FDA.
This action has been determined to be significant for the purposes
of Executive Order 12866 and, therefore, has been reviewed by the
Office of Management and Budget.
Authority: 7 U.S.C. 8301-8317; 7 CFR 2.22, 2.80, and 371.
Done in Washington, DC, this 16th day of September 2008.
Bruce Knight,
Under Secretary for Marketing and Regulatory Programs.
[FR Doc. E8-21977 Filed 9-18-08; 8:45 am]
BILLING CODE 3410-34-P